Details of the Drug Combination

General Information of Drug Combination (ID: DC00JP2)

Drug Combination Name
Nintedanib Verteporfin
Indication
Disease Entry Status REF
Ewing sarcoma Investigative [1]
Component Drugs Nintedanib   DMMQ2OW Verteporfin   DMIY6DB
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: TC-71
Zero Interaction Potency (ZIP) Score: 0.742
Bliss Independence Score: 5.741
Loewe Additivity Score: 3.567
LHighest Single Agent (HSA) Score: 2.356

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Nintedanib
Disease Entry ICD 11 Status REF
Idiopathic pulmonary fibrosis CB03.4 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [3]
Ovarian neoplasm N.A. Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Indication(s) of Verteporfin
Disease Entry ICD 11 Status REF
Choroidal neovascularization 9B76 Approved [5]
Exudative age-related macular degeneration 9B78.3Z Approved [5]
Psoriasis vulgaris EA90 Approved [6]
Verteporfin Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [7]
ATP-binding cassette sub-family B member 6 (ABCB6) DTF9Y2V ABCB6_HUMAN Substrate [8]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 205832
3 Nintedanib FDA Label
4 ClinicalTrials.gov (NCT04338802) Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19. U.S. National Institutes of Health.
5 Verteporfin FDA Label
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7 The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res. 2007 Apr 15;13(8):2463-70.
8 Efficient purification and reconstitution of ATP binding cassette transporter B6 (ABCB6) for functional and structural studies. J Biol Chem. 2013 Aug 2;288(31):22658-69.